Infl ammatory bowel disease (IBD) and celiac disease are the two most common immune-mediated gastrointestinal diseases. There is limited knowledge regarding the course of IBD in those with coexisting celiac disease. We conducted this study to determine whether patients with coexisting celiac disease present a unique phenotype of IBD and to examine the frequency of co-occurrence of celiac disease and IBD in comparison with other autoimmune disorders.
INTRODUCTION
Ulcerative colitis (UC) and Crohn ' s disease (CD) are the two predominant forms of infl ammatory bowel diseases (IBD). Th ey oft en have their onset during young adulthood and have a relapsingremitting course, requiring the use of immunomodulator (IMM) or biological therapies, hospitalizations, and surgery ( 1, 2 ) . However, there is signifi cant heterogeneity in the natural history with some patients having mild disease, but others developing early penetrating complications, requiring multiple hospitalizations and surgeries ( 1, 2 ) . Th ere is growing interest in identifying subgroups of IBD patients at higher risk of adverse outcomes. Clinical markers of aggressive disease include younger age of onset, need for steroids at diagnosis, and perianal disease ( 3 ) . In addition, genetics and serologic markers have shown promise in similarly predicting aggressive disease ( 4 -7 ) . For example, variants in the NOD2 alleles predict fi brostenotic small bowel CD and the need for early surgery in such patients ( 4 ) . Antibodies directed against luminal microbial antigens have also shown signifi cant potential in predicting aggressive disease ( 5, 6 ) . Patients with higher titers of antimicrobial antibodies (ASCA, OmpC, CBir1) have a greater likelihood of small bowel disease, penetrating complications, and need for surgery in CD ( 8, 9 ) .
Celiac disease is an autoimmune response to the protein fractions of gluten and aff ects up to 1 % of the North American
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population ( 10 -13 ) . Its manifestations can be protean and oft en resemble IBD, including symptoms of abdominal pain, diarrhea, and associated iron-defi ciency anemia ( 14, 15 ) . While the genetic basis of IBD is still incompletely understood, there is considerable overlap in genetic risk loci between CD and celiac disease. For example, PTPN2 , IL18RAP , TAGAP , and PUS10 have all demonstrated genome-wide association with both CD and celiac disease ( 16 ) . Th e only studies examining co-occurrence of the two are limited to case-reports or small case-series describing the outcomes of patients with coexisting celiac disease and IBD ( 17 -28 ) . Whether the shared genetic risk between both diseases predisposes to a more aggressive phenotype of IBD has not been examined previously. Also, whether the association between antibodies to luminal microbial antigens and severe disease also extends to antibodies against luminal dietary antigens (i.e., gluten) has also not been studied previously.
Consequently, we performed this study with the following objectives: (i) to explore whether patients with both celiac disease and IBD represent a distinct disease phenotype; (ii) to examine the prevalence of celiac disease in IBD patients, and IBD in those with celiac disease; and (iii) to compare the frequency of occurrence of celiac disease among various autoimmune diseases.
METHODS
Study population
Th is was a retrospective study including patients from two tertiary referral hospitals -Massachusetts General Hospital (MGH) and Brigham and Women ' s Hospital (BWH) -which serve over 3 million patients in the Greater Boston area. Both hospitals also serve a large number of patients from neighboring states in the Northeastern United States. We adopted a case -control design. Potential cases and controls were identifi ed through a query of the Partners Healthcare Research Practice Data Registry (RPDR), an electronic database of all patients seen at MGH, BWH, and affi liated institutions within the Partners Healthcare system. Th e RPDR is a centralized clinical data repository and query system initiated in 1996. It is automatically and continuously populated with patient data from a variety of data sources, including billing, encounter scheduling, medications, laboratory, radiology, endoscopy, and surgery databases. For diseases and procedures, encounters have been coded with International Classifi cation of Diseases, 9th edition (ICD-9-CM) codes since the inception of RPDR. Th e case population comprised of all patients with a confi rmed diagnosis of IBD (UC or CD) who also had been diagnosed with celiac disease. Th is was performed by fi rst performing broad searches using ICD-9-CM codes for CD (ICD-9-CM 555.x) or UC (ICD-9-CM 556.x) in combination with a diagnosis code for celiac disease (ICD-9-CM 579.0) or abnormal celiac serology testing (anti-tissue transglutaminase immunoglobulin-G (IgG) or IgA, anti-endomysial antibody, or anti-gliadin antibody). A chart review of the electronic medical records was then performed for every potential case identifi ed to confi rm the diagnoses of coexisting IBD and celiac disease using standard clinical, radiographic, endoscopic, and histological criteria. For celiac disease, this included an abnormal serologic test and duodenal histology demonstrating some degree of villous atrophy where available and if the patient had not been previously started on a gluten-free diet. A diagnosis of CD or UC required the presence of typical symptoms of at least 3 months duration in combination with compatible endoscopic (or radiologic fi ndings) fi ndings and histology demonstrating chronic infl ammation. Patients with microscopic colitis were excluded from the study. All potential patients received at least one diagnosis code for CD, UC, or celiac disease aft er 1996. To identify controls, the RPDR was queried for a set of random controls with a diagnosis of IBD alone without a coexisting ICD-9-CM code for celiac disease. For each case, we identifi ed two randomly selected controls from this population through computer-generated random numbers, matched on IBD type (CD or UC or indeterminate colitis), aft er further confi rming the absence of coexisting celiac disease through chart review.
Study variables and outcomes
Demographic and disease variables were obtained from electronic medical records and included age, gender, ethnicity, age at diagnosis and duration of IBD, and type of disease (CD vs. UC). Th e Montreal Classifi cation was used to categorize disease behavior (infl ammatory, stricturing, or penetrating) and location (ileal, colonic, ileocolonic) in CD ( 29 ) . Upper gastrointestinal involvement and perianal disease formed non-mutually exclusive categories of disease location and behavior. Disease extent in UC was classifi ed as extensive (beyond splenic fl exure) or limited colitis. We also recorded information on current and prior (ever use) use of therapy compared to never use, including 5-ASA, oral corticosteroid (prednisone and budesonide), IMM (methotrexate, azathioprine, and 6-mercaptopurine), and biologic therapy (infl iximab, adalimumab, certolizumab pegol, and natalizumab). Smoking status was classifi ed into ever or never smoking based on history. Within the cohort of patients with celiac disease, information was obtained on how we were able to confi rm the diagnosis of celiac disease (serology, endoscopy, biopsy, or established clinical history alone). We also assessed whether the patient had ever followed a gluten-free diet through references to such adherence within the electronic medical record. Additional information extracted from the medical record included history of IBD-related hospitalizations and surgeries, presence of another autoimmune disease in addition to IBD, or celiac disease.
Disease prevalence
To examine the relative prevalence of celiac disease among CD, UC, and other autoimmune diseases, we queried the RPDR for the proportion of patients with each of several immune-mediated diseases who also had a coexisting ICD-9-CM code for celiac disease ( Supplementary Table S1 online).
Primary outcomes and statistical analysis
Our primary comparisons were of disease phenotype (extent, behavior) and natural history (need for surgery and hospitalizations) between celiac-IBD cases and non-celiac controls. Data were analyzed used Stata 11.0 (StataCorp, College Station, TX).
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Continuous variables were summarized with means and standard deviations, while categorical variables were described using proportions. Th e t -test was used to compare continuous variables. Categorical variables were compared using the χ 2 -test with the use of the Fishers ' exact test when appropriate. Multivariate logistic regression analysis was used to determine the independent association of our outcomes of interest for celiac disease, adjusting for potential confounders. All P values < 0.05 were considered statistically signifi cant.
Th e study was approved by the Partners Healthcare Institutional Review Board.
RESULTS
Study population
A total of 51 IBD patients with celiac disease and 102 IBD controls without celiac disease were included in our study. Th e years of IBD diagnosis ranged from 1966 to 2012. Figure 1 presents the methods of confi rmation of celiac disease diagnosis. In nearly half of the patients, we could confi rm diagnosis by review of both serology and biopsy results, whereas one-quarter of the patients had an established clinical history and confi rmed diagnosis of celiac disease from a non-Partners institution without details regarding their actual testing available in our Electronic Medical Record (EMR) ( n = 12, 23.5 % ). In patients diagnosed with sero logy alone, all had elevated anti-tissue transglutaminase anti bodies and anti-endomysial antibodies. Among those diagnosed with serology and biopsy, three patients had positive anti-endomysial antibodies alone, two had positive anti-gliadin antibodies alone (antitissue transglutaminase not checked in these fi ve patients). Th e rest all had positive anti-tissue transglutaminase IgA, most in combination with elevated anti-endomysial antibodies when these were checked. For two patients, only a notation that serology was positive was available in the medical record without specifying the type of serologic marker. A majority (92.2 % ) of the celiac-IBD patients reported following a gluten-free diet either continuously or intermittently. Table 1 compares the characteristics of the celiac-IBD cases and non-celiac IBD controls. Th e mean age at IBD diagnosis (27.3 vs. 28.7 years, P = 0.65) and gender distribution (58.8 vs. 57.8 % female, P = 0.91) were similar between the two groups, while the mean duration of disease was slightly shorter in the celiac-IBD group. Th ere was a numerical higher proportion of other autoimmune diseases among the celiac-IBD group (23.5 % ) as compared with non-celiac controls (12.8 % , P = 0.09).
Phenotype differences between celiac-IBD cases and non-celiac IBD controls
As seen in Table 1 , presence of pancolitis was more common in celiac-UC patients as compared with non-celiac UC controls (63.2. vs. 35.9 % , odds ratio (OR) 3.30, 95 % confi dence interval (CI) 1.05 -10.39). We conducted a sensitivity analysis to determine whether the phenotypic diff erences also applied to the cohort of celiac-UC patients whose celiac diagnostic test results could directly be confi rmed within our EMR through review of both serology and histology. Within this group, there was a similarly increased prevalence of the pancolitis phenotype as compared with the non-celiac UC controls (75.0 vs. 35.9 % , OR 5.8, 95 % CI 1.55 -21.50). Th ere was no diff erence in the age of diagnosis between celiac-UC compared with non-celiac UC controls.
In contrast, for CD, we did not fi nd any diff erence in disease behavior (infl ammatory, structuring, or fi stulizing) between the two groups ( Table 1 ). Disease location was also similar between the celiac-CD cases and non-celiac CD controls with respect to the terminal ileum, colon, and ileocolon ( P = 0.48). Additionally, the rates of upper gastrointestinal tract (16.7 vs. 9.3 % , P = 0.45) or perianal (8.3 vs. 22.2 % , P = 0.21) involvement in the celiac-CD patients as compared with the non-celiac group were similar. Patients in the celiac-IBD group were signifi cantly less likely to be ever-smokers than non-celiac IBD controls (26.7 vs. 45.1 % , OR 0.44, 95 % CI 0.21 -0.95). Th e increased likelihood of ever-smoking among the control group persisted when compared with celiac-IBD patients whose celiac disease diagnostic test information was available in our EMR (24.2 vs. 45.1 % , OR 0.39, 95 % CI 0.16 -0.95).
Outcomes in celiac-IBD compared with non-celiac IBD controls
As seen in Table 2 , there was a trend toward increased use of IMMs among celiac-UC patients than in non-celiac UC controls (45.5 vs. 22.7 % , OR 2.83, CI 95 % 0.95 -8.48). Th ere was no notable diff erence in IMM use between celiac-CD patients compared with the non-celiac CD controls. Th e presence of coexisting celiac disease also did not infl uence the usage rate of 5-ASAs, oral corticosteroids, or biologics among CD or UC patients ( Table 2 ). Th ere were no diff erences in IBD-related hospitalizations or surgeries between cases and controls.
Clustering of celiac, IBD, and other autoimmune diseases
We examined the prevalence of celiac disease among all patients with a diagnosis code for CD or UC. We found a prevalence of celiac disease among CD and UC of 1.27 % and 1.04 % , respectively within the Partners Healthcare system, which is similar to the prevalence estimates of celiac disease among the general North American population ( 10 ) . In contrast, the prevalence of CD or UC among those with a diagnosis code for celiac disease in the Partners Healthcare system was signifi cantly greater at 4.0 % 
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Oxford et al. and 3.2 % , respectively, suggesting that while patients with IBD may not be at a higher risk for celiac disease, those with underlying celiac disease may be much more likely to have CD or UC. Th e prevalence of a diagnosis code for celiac disease was much less common in those with other autoimmune diseases including rheumatoid arthritis (0.54 % ), systemic lupus erythematosus (SLE) (0.84 % ), psoriasis (0.52 % ), Type 1 diabetes (0.69 % ), or multiple sclerosis (0.26 % ) ( Figure 2 ).
DISCUSSION
Infl ammatory bowel disease (CD and UC) and celiac disease are the two most common immune-mediated gastrointestinal diseases and share common genetic risk variants ( 16, 30 ) . However, there have been few previous studies that have examined the association between the two diseases; and in particular, clinical outcomes of IBD in the presence of coexisting celiac disease have not been previously well-characterized.
Our data show that patients who have both celiac disease and UC are more likely to have pancolitis as opposed to more limited colonic infl ammation, despite having a shorter duration of UC disease than our non-celiac UC controls. Th is is similar to a few previous studies that have examined other coexisting autoimmune diseases in UC. For example, UC patients with primary sclerosing cholangitis (PSC) are similarly more likely to have pancolitis as opposed to patients with isolated UC ( 25, 31 ) . A previous case series of IBD patients with celiac disease similarly found four out of fi ve patients with UC and celiac disease to have pancolitis ( 28 ) . Th us, patients with UC and coexisting celiac disease or PSC may represent a unique autoimmune-related phenotype of UC. However, further studies with other concomitant autoimmune diseases would be essential to defi ne this further. We also identifi ed a trend toward increased use of IMMs among the celiac-UC cohort. However, there was no signifi cant diff erence in other IBD medications, hospitalizations, or surgeries. Th ese fi ndings diff er from some of the small early case reports that postulated that patients with a combination of UC and celiac disease were more likely to have severe disease requiring colectomy ( 28 ) . However, as the study by Yang et al. ( 28 ) was also from a referral center but had no nonceliac UC controls for comparison, it is diffi cult to estimate if the rate of colectomy in that exceeded that in non-celiac UC patients.
We also did not fi nd any eff ect of coexisting celiac disease in infl uencing disease phenotype or natural history in CD. A previously published review of eight cases found that CD manifested in atypical locations when in conjunction with a celiac disease diagnosis; however, our study shows no signifi cant diff erence in CD location in the presence of celiac disease ( 27 ) . Th e lack of signifi cant diff erences in the clinical outcomes of patients with celiac disease and CD may argue against an eff ect of the shared risk loci between CD and celiac disease in infl uencing the natural history of disease. It may also be indicative that the association between immunological response seen against luminal microbial antigens and severe disease may not extend to dietary antigens such as gliadin.
An interesting observation was that patients in the celiac-IBD group were less likely to have been ever-smokers than controls, which is consistent with previously published studies, have also found lower smoking rates in patients diagnosed with celiac disease and have suggested a protective role of cigarette smoking ( 32 ) . Smoking has similarly been found to have a protective eff ect on UC and PSC, again highlighting the possibility of a common link in the 
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Celiac Disease and IBD be expected in the general population as has been reported previously ( 19, 24, 28 ) . Th is suggests that in patients with celiac disease, particularly in those with non-response to gluten-free diet, one should consider work up for possible underlying IBD as this may exist concurrently in such patients. Th ere is limited data to compare prevalence of celiac disease among other autoimmune diseases. We found a lower prevalence of celiac disease in Type I diabetics than has been reported elsewhere (0.7 % vs. 4 -9 % ) ( 35 ) . Th e true prevalence of the comorbidity of celiac disease with other autoimmune disorders such as RA and SLE has not been previously well-established ( 36,37 ) and merits further analysis pathogenesis of these immune-mediated diseases. Our celiac-IBD patients were more likely to be affl icted with other autoimmune diseases than non-celiac IBD controls, highlighting the shared genetic susceptibility many of these patients may have. Indeed, shared genetic risk loci have been described between celiac disease and CD, Type I diabetes, and rheumatoid arthritis ( 16, 33, 34 ). An important fi nding from our study is that while the prevalence of celiac disease in IBD patients within the Partners database was similar to what was expected in the general North American Caucasian population (10), the prevalence of IBD among those with celiac disease was considerably higher than would 
in larger validated disease cohorts, and where possible with prospective structured screening for celiac disease. Ludvigsson et al. ( 38 ) recently identifi ed a threefold increase in risk for SLE among those with biopsy-proven celiac disease. Th ere are a few potential explanations for the potentially higher frequency of celiac disease among IBD compared with other autoimmune diseases. First, this could represent an ascertainment bias. As celiac disease and IBD are both managed commonly by gastroenterologists, there may be a lower threshold to obtain celiac serology testing or endoscopic biopsies in such patients compared with those managed by nongastroenterologist physicians. Second, the higher frequency of celiac disease among IBD compared with other autoimmune diseases could also be consequent to the greater degree of genetic overlap between celiac disease and IBD than that observed with other diseases. Th e higher prevalence of IBD in those with celiac disease, but not celiac disease in those with IBD, may be due to the multifactorial etiopathogenesis of both diseases in which the development of disease requires a combination of environmental and genetic infl uences, and shared genes contribute a diff erential fraction of the disease risk for both diseases.
We believe that there are few clinical implications to our fi ndings. First, reassuringly we did not identify a more aggressive phenotype of disease in those with coexisting celiac disease and IBD. Consequently, we do not suggest any need to modify current practice patterns in the management of IBD in this cohort of patients with the exception of recognizing the higher frequency of pancolitis among celiac-UC patients. Second, recognizing a possible higher prevalence of IBD among those with celiac disease, celiac disease patients with persistent gastrointestinal symptoms, despite a gluten-free diet, should also potentially trigger evaluation for underlying IBD (in addition to standard practice of evaluating for inadvertent gluten ingestion as well as underlying refractory celiac disease or lymphoma).
Th ere are a few limitations to our study. First, referral bias is possible in studies at large tertiary centers. However such bias is unlikely to aff ect our results because both the case and controls groups were taken from the same pool of patients in the Partners database. As with any retrospective study, the level of past documentation aff ects completeness and quality of data collected. In our study, due to gaps in data, we were not able to consistently determine whether IBD or celiac disease was diagnosed fi rst, or the symptoms / signs that led to diagnosis of celiac disease. It is possible that the order in which a patient is affl icted with the diseases may have some eff ect on outcome and further investigation is warranted in this area. Owing to the retrospective nature of the study, it was not possible to obtain serologic testing for all of the included patients; therefore, there is a possibility that some patients in our control group have " silent " or asymptomatic celiac disease ( 39 ) . However, given the expected prevalence of this being less than 1 % , it is unlikely to have infl uenced our results. Finally, we also acknowledge the possibility of false-positive fi ndings due to simultaneous comparison of multiple patient characteristics and outcomes. As this is an exploratory study with limited prior literature in this area, we did not correct for multiple hypothesis testing within the context of this study. Consideration for this should be given in larger cohorts further characterizing and confi rming the phenotype of celiac-IBD patients.
In summary, to our knowledge, this is the fi rst case -control study examining clinical outcomes of patients with concurrent diagnoses of celiac disease and IBD to non-celiac IBD controls. While patients with celiac disease and UC may be more likely to have pancolitis, it is not clear that having the two diseases simultaneously leads to worse outcomes. However, while celiac disease is not more common in those with CD or UC, coexisting IBD seems to occur more commonly in patients with celiac disease.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Celiac disease and infl ammatory bowel diseases (IDB) are common immune-mediated diseases of the gastrointestinal tract.
3 Celiac disease occurs in 1 % of the North American population.
3 Whether coexistence of IBD and celiac disease represents an unique disease phenotype is unknown.
WHAT IS NEW HERE
3 Ulcerative colitis (UC) patients with coexisting celiac disease have a higher frequency of pancolitis than non-celiac UC controls.
3 UC-celiac patients also had a trend toward greater use of immunomodulators.
3 Coexisting celiac disease did not infl uence phenotype or natural history of Crohn ' s disease.
